Clover Health Investments, Corp. (CLOV) Guidance & Earnings Results

On 2026-08-05 Clover Health Investments, Corp. raised guidance: "Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CLOVClover Health Investments, Corp.Follow CLOV — free

Healthcare Plans · Healthcare

—

Price chart with a free account

Market cap: 2.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to $20M-$35M · full year
6 May 26	Raised	FY2026 revenue $2.81B-$2.92B (midpoint $2.865B, +49% YoY); Gross profit $470M-$510M; Adj EBITDA $50M-$70M; GAAP Net Income $0M-$20M · full year
26 Feb 26	Raised	Revenue guidance $2.81B-$2.92B (+49% YoY midpoint); GAAP Net Income $0-$20M (first-ever profitability) · full year
5 Aug 25	Raised	FY25 Average Medicare Advantage membership raised to 104,000-108,000 from 103,000-107,000; FY25 Adjusted SG&A improved to $335M-$345M from $355M-$365M; FY25 Insurance BER raised to 88.5%-89.5% from 87%-88%; FY25 Insurance revenue maintained at $1.800B-$1.875B; FY25 Adjusted EBITDA maintained at $50M-$70M; FY25 Adjusted Net income maintained at $50M-$70M · full year

Clover Health Investments, Corp. — questions

What guidance did Clover Health Investments, Corp. give?: On 2026-08-05: "Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to $20M-$35M"
When does Clover Health Investments, Corp. report earnings?: Clover Health Investments, Corp.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from Clover Health Investments, Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.